Apr 17 |
Here's Why Corvus (CRVS) is Poised for a Turnaround After Losing -25% in 4 Weeks
|
Apr 9 |
Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
|
Apr 1 |
Down -18.35% in 4 Weeks, Here's Why Corvus (CRVS) Looks Ripe for a Turnaround
|
Mar 22 |
Corvus (CRVS) Upgraded to Buy: What Does It Mean for the Stock?
|
Mar 21 |
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2023 Earnings Call Transcript
|
Mar 20 |
Q4 2023 Corvus Pharmaceuticals Inc Earnings Call
|
Mar 20 |
Corvus Pharmaceuticals, Inc. (CRVS) Q4 2023 Earnings Call Transcript
|
Mar 19 |
Corvus Pharmaceuticals GAAP EPS of -$0.14 misses by $0.01
|
Mar 19 |
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
|
Mar 13 |
Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024
|